ASCO 2024: Updates in Multiple Myeloma : Episode 2
Opinion
Video
Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.
Video content above is prompted by the following:
- Discuss the data you presented at the 2024 ASCO Annual Meeting on long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM).
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
